Antiretroviral therapy (ART) suppresses plasma and cerebrospinal fluid (CSF) HIV replication. Neurosymptomatic (NS) CSF escape is a rare exception in which CNS HIV replication occurs in the setting of neurologic impairment. The origins of NS escape are not fully understood. We performed a case-control study of asymptomatic (AS) escape and NS escape subjects with HIV-negative subjects as controls in which we investigated differential immunoreactivity to self-antigens in the CSF of NS escape by employing neuroanatomic CSF immunostaining and massively multiplexed self-antigen serology (PhIP-Seq). Additionally, we utilized pan-viral serology (VirScan) to deeply profile the CSF anti-viral antibody response and metagenomic next-generation sequencing (mNGS) for pathogen detection. We detected Epstein-Barr virus (EBV) DNA more frequently in the CSF of NS escape subjects than in AS escape subjects. Based on immunostaining and PhIP-Seq, there was evidence for increased immunoreactivity against self-antigens in NS escape CSF. Finally, VirScan revealed several immunodominant epitopes that map to the HIV envelope and gag proteins in the CSF of AS and NS escape subjects. Whether these additional inflammatory markers are byproducts of an HIV-driven process or whether they independently contribute to the neuropathogenesis of NS escape will require further study.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneuroim.2023.578141DOI Listing

Publication Analysis

Top Keywords

csf escape
16
escape subjects
16
escape
11
csf
9
csf hiv
8
hiv replication
8
immunoreactivity self-antigens
8
hiv
5
subjects
5
viral co-infection
4

Similar Publications

The incidence of symptomatic CSF viral escape in patients on antiretroviral therapy in western India: a retrospective cohort study.

J Neurovirol

November 2024

Research Methodology and Biostatistics Core, Office of Research, Department of Internal Medicine, Morsani College Of Medicine, University of South Florida, Tampa, FL, USA.

Antiretroviral treatment (ART) effectively suppresses viral loads in both plasma and cerebrospinal fluid (CSF). Patients with discordant plasma and CSF viral loads may experience chronic-progressive or fluctuating neurocognitive dysfunctions. This study examined the incidence of symptomatic CSF viral escape (CSFVE) in patients receiving ART.

View Article and Find Full Text PDF

Asymptomatic Cerebrospinal Fluid HIV-1 Escape: Incidence and Consequences.

J Infect Dis

November 2024

Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Article Synopsis
  • * Among the participants, asymptomatic CSF-E was found in only 2% of individuals and 1% of samples, indicating a low incidence.
  • * While CSF-E was linked to signs of immune activation and potential blood-brain barrier issues, it did not correlate with indicators of neuronal damage.
View Article and Find Full Text PDF

Background/aim: Alzheimer's disease (AD) is the most common form of dementia worldwide. Nattokinase is a serine protease extracellularly produced by natto, a fermented product of Bacillus subtilis var. natto.

View Article and Find Full Text PDF

CSF d18:1 sphingolipid species in Parkinson disease and dementia with Lewy bodies with and without GBA1 variants.

NPJ Parkinsons Dis

October 2024

Center of Neurology, Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany.

Article Synopsis
  • Variants in the GBA1 gene lead to changes in sphingolipid levels, which are lipid molecules important for cell function.
  • A study analyzed five specific sphingolipid species in the cerebrospinal fluid (CSF) of individuals with Parkinson's Disease and Dementia with Lewy bodies, both with and without GBA1 variants, as well as healthy controls.
  • The results showed no increase in sphingolipid levels in participants with the GBA1 variant and no link to cognitive decline, indicating that these sphingolipids are not useful as indicators of Parkinson's Disease.
View Article and Find Full Text PDF

Vaccine-based therapeutics for cancers face several challenges including lack of immunogenicity and tumor escape pathways for single antigen targets. It has been reported that radiotherapy has an in situ vaccine effect that provides tumor antigens following irradiation, helping to activate antigen-presenting cells (APCs). Herein, a new vaccine approach is developed by combining genetically engineered irradiated tumor cell debris (RTD) and hyaluronic acid (HA), termed HA@RTD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!